Insider Selling: Pharvaris (NASDAQ:PHVS) Director Sells $241,424.40 in Stock

Pharvaris N.V. (NASDAQ:PHVS) Director Johannes Gerardus Chri Schikan sold 6,888 shares of the firm’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $35.05, for a total transaction of $241,424.40. Following the completion of the sale, the director owned 345,879 shares of the company’s stock, valued at approximately $12,123,058.95. The trade was a 1.95% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Johannes Gerardus Chri Schikan also recently made the following trade(s):

• On Tuesday, June 30th, Johannes Gerardus Chri Schikan sold 30,712 shares of Pharvaris stock. The stock was sold at an average price of $35.49, for a total value of $1,089,968.88.
• On Thursday, April 30th, Johannes Gerardus Chri Schikan sold 29,070 shares of Pharvaris stock. The shares were sold at an average price of $30.32, for a total value of $881,402.40.
• On Wednesday, April 29th, Johannes Gerardus Chri Schikan sold 3,830 shares of Pharvaris stock. The stock was sold at an average price of $30.07, for a total value of $115,168.10.
• On Thursday, April 23rd, Johannes Gerardus Chri Schikan sold 100 shares of Pharvaris stock. The stock was sold at an average price of $30.03, for a total value of $3,003.00.
• On Wednesday, April 22nd, Johannes Gerardus Chri Schikan sold 7,000 shares of Pharvaris stock. The stock was sold at an average price of $30.05, for a total transaction of $210,350.00.

Pharvaris Stock Performance

Shares of NASDAQ PHVS opened at $33.86 on Friday. Pharvaris N.V. has a one year low of $17.05 and a one year high of $35.90. The firm has a market capitalization of $2.21 billion, a P/E ratio of -10.65 and a beta of -2.34. The company’s fifty day moving average is $31.07 and its two-hundred day moving average is $28.32.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($0.82) by $0.12. On average, sell-side analysts forecast that Pharvaris N.V. will post -3.2 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently issued reports on PHVS shares. Wedbush lifted their price objective on Pharvaris from $41.00 to $42.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 7th. Royal Bank Of Canada lowered their target price on Pharvaris from $52.00 to $51.00 and set an “outperform” rating on the stock in a report on Monday, April 6th. Wall Street Zen raised Pharvaris from a “sell” rating to a “hold” rating in a research report on Saturday, June 6th. Morgan Stanley boosted their price target on Pharvaris from $41.00 to $46.00 and gave the stock an “overweight” rating in a report on Thursday, June 25th. Finally, Wolfe Research started coverage on Pharvaris in a research report on Thursday, April 9th. They issued an “outperform” rating and a $42.00 price objective on the stock. Ten investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $49.64.

Institutional Trading of Pharvaris

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PHVS. GF Fund Management CO. LTD. purchased a new position in shares of Pharvaris during the 4th quarter worth about $35,000. Barclays PLC purchased a new stake in Pharvaris in the fourth quarter valued at approximately $77,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in Pharvaris during the fourth quarter worth approximately $86,000. JPMorgan Chase & Co. increased its position in Pharvaris by 30.6% during the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after purchasing an additional 783 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Pharvaris during the fourth quarter worth approximately $110,000.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.